Market Trends of Iran Diabetes Care Devices Industry
Management Devices Hold Highest Market Share in Iran Diabetes Care Devices Market
Type 1 diabetes (T1D) patients must maintain good lifestyle conditions influenced by a person's personality qualities, social interactions, socioeconomic situations, and environmental living variables. Continuous glucose monitoring (CGM) combined with multiple daily injections (MDI) has been demonstrated to reduce nonsevere and severe hypoglycemia in persons with T1D prone to this side event. Patients with T1D at high risk of hypoglycemia can employ standalone continuous glucose monitoring to regulate their blood sugar levels even in the terrible living conditions imposed by the COVID-19 pandemic crisis's draconian lockdown.
Diabetes patients in Iran face financial hardship. Pharmacies do not sell enough insulin to people with diabetes; instead, insulin is sold at a higher price on the open market. Sometimes the parent of a diabetic child is unable to locate insulin. Insulin costs 20-30% of a family's monthly income for children and adults with type 1 diabetes. This does not include the cost of test strips and other supplies, which are extremely costly. Furthermore, insurance companies in Iran are reducing financial support for diabetic treatments. The availability of insulin is restricted, and Iranian families with diabetic children cope by reducing the number of carbohydrates in their child's diet.
Despite all these, in Iran, usage of Insulin management devices increasing over the years.
Increasing Type -1 Diabetes Population in Iran
Diabetes is a serious public health concern in Iran, the Middle East's second-largest country, due to its high prevalence rate, growing occurrence rate, and economic impact. It is estimated that by the year 2030, 9.2 million Iranian individuals will have diabetes. Diabetes-related mortality in Iran continues to rise; the age-standardized death rate from diabetes has risen. Diabetes has significant economic consequences in the country. Diabetes and its high direct healthcare costs are significant risk factors for chronic illnesses like cardiovascular disease.
Diabetes complications, for example, accounted for USD 412 (49%) of the USD 843 per capita cost of diabetes. Yazd, a world heritage city in the center of Iran, has one of the highest recorded prevalences of DM in Iran. Other cities in Iran have varying levels of DM awareness. For example, in Kerman, a province south of Yazd, the prevalence of undiagnosed diabetes is only 2.7%, but it is 25% in northern Iran.
Despite the widespread availability of drugs and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia, and hypertension (particularly among young men and women) remains inadequate.
As a result, Iran's diabetes care devices market is predicted to expand gradually in the coming years.
